Generate BiomedicinesGENB
Recorded

Generate Biomedicines Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration22 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael NallyCEO

All right. Well, good morning, everybody. It's a real pleasure to be here. My name is Mike Nally. I'm the CEO of Generate Biomedicines, and excited to share a little bit about the work we've been doing over the past eight years to try and usher in an era of programmable biology. Here's our forward-looking statement. Generate's been at the forefront of what we think is a pretty material shift in how we explore biology. Around nine years ago, the technology industry started to open up opportunities using the transformer architecture to understand complex domains with a data-driven approach. Over the past eight years, Generate has been pursuing this with a distinct focus on making proteins programmable. What we've been able to show is that through an integrated dry and wet lab, our ability to explore biology continues to progress very, very quickly.

Michael NallyCEO

In the last year, we've really pushed hard, given the tools that the large language models are enabling, to create an agentic native infrastructure. What we're finding now is that we have a suite of molecular design capabilities that allow us to pursue very difficult therapeutic tasks, whether that be through internalization, through selectivity, through pH-dependent binding. A whole range of very difficult-to-drug domains are starting to become druggable using protein-based therapeutics. We've been fortunate to work with some extraordinary collaborators. We did our first partnership with Amgen back in 2021. We extended that work with Novartis in 2024. We're working with now, most recently, Zealand Pharma in the obesity space, using these sort of technologies. One of the things that excites me about the opportunity is that the technology is translating very, very quickly. Five and a half years ago, we had no therapeutic programs.

Michael NallyCEO

We were purely a technology company. Our lead asset entered phase III trials in under five years. In the chronic care space, that's pretty quick. What we're seeing is an ability not only to accelerate the time to therapeutic innovation, but also a very clear ability to drug domains that were almost impossible to drug in the past. Our second program is looking at this with a protein that binds the toxin of MMAE-based ADCs. This was a really difficult toxin to drug, but we've been able to create a molecule that is specific to that toxin without interrupting the intact ADC. So, where in the first instance we've shown an ability to come up with better answers to existing therapeutics, what we're seeing in subsequent rounds of innovation is the ability to drug more undruggable domains. The pipeline starts with GB-0895. This is an anti-TSLP molecule.

Michael NallyCEO

The molecule has some exquisite characteristics, a half-life of 98 days, the binding affinity of 106 femtomolar. We moved it into phase III trials in asthma in December of last year. We'll talk more about this in a little bit. We're also investigating it in COPD. We shared some data at the European Respiratory Society in September that showed our ability to effectively modulate the key biomarkers of FeNO, IL-5, and IL-13 out to six months in COPD. GB-4362 is the molecule I mentioned a moment ago. This is the ADC toxin neutralizer. That molecule is rapidly enrolling in its phase I dose-finding portion of the trial. Once we complete the dose finding early next year, we will likely push into an expansion cohort to see whether or not we're able to stop the progression from grade 1 to grade 2 of neuropathy.

Michael NallyCEO

GB-5267 is an armored CAR T program that we are working with our partners at Roswell Park on. The team at Roswell Park are some of the best innovators in the cell therapy space. They had asked us, could we use our technology to optimize the binder and framework for CAR T therapies? What we have been able to find is probably the most potent CAR T to be investigated in solid tumors, and that is enrolling in a phase I trial in Buffalo, New York. As I mentioned a moment ago, we have a range of different partnerships. We do think this is a new era. We do think these technologies will allow us to not only help enable the ability to design molecules that are transformative and out of the reach of current protein engineering approaches, but also change the underlying process of drug discovery.

Michael NallyCEO

I will share a little bit more about both sides of that equation in subsequent slides. One of the benefits of this is what we are seeing is a much bigger and cheaper early exploration of biology. We are seeing a time advantage, but also, importantly, the quality advantages are starting to be realized, where we are able to go after things that were previously undruggable. Our partnerships have been a great asset in this regard. Working with teams at Amgen, working with teams at Novartis, some of the best protein engineers on the planet, when they cannot solve problems and we start to use our technology to be able to solve those domains, it tells us these are getting after undruggable pockets. That is one of the things I think that excites us most about the future of this programmable biology space.

Michael NallyCEO

At the core of the company is this integrated dry and wet lab. I think oftentimes when you hear AI drug discovery, people think of models. Certainly the models are important and will continue to push the frontiers of computational models, but the amount of innovation experimentally is as profound as it is computationally. You see one of our scientists on the lower right-hand side of this chart, Kirsten. She is holding a test tube. In that test tube, we are doing 10 billion purposefully designed variants to drive an experiment around pH-dependent binding. This allows you to find the gradient in really complex domains of biology to really fully leverage these computational advantages. We will push the frontiers of computational modeling, but we will also push the frontiers of experimental innovation. On the other side, on the left-hand side here, you see our scientist, Claudio.

Michael NallyCEO

He is working on our cryo-EM studio. We bought four cryo-EM microscopes about four years ago, and what Claudio has been pushing on is making cryo-EM a high-throughput instrument. All of these protein engineering models have been trained on the Protein Data Bank. The Protein Data Bank has about 200,000 high-quality, high-resolution structures of proteins. What Claudio and the team are doing are actually solving structures where our protein folding models have low confidence. It is expanding the universe of effective exploration of proteins. Secondly, they are also creating new data types. While most of the Protein Data Bank are static images of proteins, what Claudio and the team are doing by both experimental resolution, but then deconvoluting using machine learning practices, is actually moving it to a 3D image of the protein in its dynamic state.

Michael NallyCEO

And so almost solving the video of the protein interaction. That data, we think, will be very powerful in feeding our models into the future. We were fortunate around the turn of the year to really have some scientists that said, "A new way of discovery is upon us." We were fortunate to work with our partners at Anthropic around how we could leverage agentic science to explore biology in a different way. This was largely as coding agents became more and more powerful. We asked ourselves, could we take on a very complex scientific domain using these sort of approaches? We put six scientists into a room. We gave them a budget of $250,000, asked them to explore and reason over a complex domain of biology.

Michael NallyCEO

They chose the intracellular signaling domain of in vivo CAR T as the domain that they wanted to reason over. That has been largely static over the past few years. We typically use the 4-1BB CD3 zeta signaling domain. Basically, could they distill it down to the essential elements and ultimately to create space to add additional cargo to the delivery vehicles in in vivo CAR T? This team of six scientists over the past six months have now come up with answers that are 70% shorter and driving a logarithmic improvement in function. We're seeing with these sort of tools, with great scientists, with a rapid verification engine, the ability to pursue complex domains of biology in very, very short order. These are just the early results. So you see up on the left-hand side the traditional design.

Michael NallyCEO

You see these refactored leads over on the right-hand side, and what you're seeing is a left-hand shift in tumor cell killing. You're seeing an increase in cytokine release. You're seeing, not shown on this slide, a log improvement in surface expression. You're seeing improvements in durability. Ultimately, what that's now leading to is a big shift down in B-cell depletion. We think this technology has application across five or six different very meaningful therapeutic domains, whether that be hematological malignancy, solid tumors, immune reset, and fibrosis. So the technology now is being pushed forward in those different domains. Over the next 12 to 18 months, it's going to be a busy time at Generate. We think our lead program, GB-0895, continues to make great progress in asthma. We hope to fully enroll the study by the end of next year, the two studies.

Michael NallyCEO

The GB-4362, our MMAE neutralizer, we should have the phase I results from the dose-finding portion in the first part of next year. We will quickly go into an expansion cohort and should have that data by the end of next year, which should show proof of concept in our ability to reduce peripheral neuropathy. GB-5267, we should have early phase I results. Then, based on the productivity of the platform, we'd expect to do one or two more strategic collaborations over the course of the next 12 months. So, a lot on the horizon for Generate. Maybe I'll just quickly dive into GB-0895, our lead asset. This is our best-in-class TSLP antibody. As I mentioned earlier, we started the phase III trial in December of last year.

Michael NallyCEO

We believe this gives us an advantage over all other long-acting anti-TSLPs, given that we started the phase III about nine months earlier than anyone else. The molecular properties, as I mentioned a moment ago, are best in class. The half-life at 98 days compares favorably. The binding affinity compares favorably. Ultimately, we believe the unmet medical need here is really, really profound. The severe asthma market is only about 20% penetrated, and we believe a six-monthly alternative will be very well received by both patients and health systems around the world. This is the opportunity set. We see 1.9 million biological eligible patients in asthma, an even bigger opportunity in COPD, and a vastly under-penetrated market in COPD. Beyond those first two indications, we see utility across a number of other domains. We obviously saw recent data from tezepelumab in EOE that looked very promising.

Michael NallyCEO

Chronic rhinosinusitis has shown proof of concept. We think this molecule offers a pipeline and a product-type potential. The early data on GB-0895 from the phase I study showed a 98-day half-life. The ability to modulate key biomarkers across FeNO, EOS, IL-5, and IL-13 were at the same or better levels than tezepelumab at all time points. Our target saturation based on our PK/PD modeling showed 99.9% target engagement across that six-month period. The safety and ADA rates were unremarkable, just as we like to see those sort of things. As I mentioned earlier, we were able to migrate directly from phase I in mild to moderate asthmatics into a phase III trial with regulatory support in severe asthma across a severe asthma population. These are the biomarker reductions, as I mentioned a moment ago. You can see how they compare to tezepelumab.

Michael NallyCEO

This is using one dose of GB-0895 at day one, measuring at six months, versus a monthly dose of tezepelumab measured at six months in a comparable population. The phase III studies are up and running. We had two replicate designs measuring a primary endpoint of asthma exacerbation rate at 52 weeks. The key secondary endpoint is the reduction in asthma exacerbation rate in the less than 300 EOS cohort. The trial is powered for actually that key secondary endpoint at 94% power of a 40% reduction in that key secondary. That means we're 99% powered in the primary endpoint. The studies have now been approved in all regions. We're enrolling across 400 different sites. The early progress is suggestive that we'll continue to complete the trial by the end of next year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day